Psych Capital PLC (AQSE:PSY), a psychedelic medicines media and investment company, completed its initial public offer in London on the Aquis Exchange
The company operates the PSYCH business-to-business data, intelligence and media platform for the psychedelic science and healthcare industry and has started to carry out events under the PSYCH Symposium banner, with its inaugural conference last month being sold out and a second planned for next year.
Its first investment portfolio addition was a stake in Awakn, a psychedelics research and clinical group with operations in the UK and Europe and listed on Canada’s NEO Exchange.
The company said it “will particularly seek to focus on identifying and supporting, strategically and financially early-stage companies that provide ancillary products and services which serve the medical psychedelic sector, primarily in the UK, across Europe and other internationally recognised jurisdictions (such as Canada), which have well-developed and reputable laws and regulations supporting the research and production of psychedelic medicines”.
Chief executive and co-founder William Potts, aged 25, is said to have been “an active investor in psychedelics healthcare since 2020”, and “brings an extensive network of high net worth and institutional investors to the table”.
He co-founded cannabis investment firm Goodplant Ventures in 2021.